Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta-analysis of Adverse Outcomes
ConclusionBoth drugs are generally safe for treating ACS patients with HBR at baseline, although a higher risk of MI was observed with the use of clopidogrel. Nevertheless, drug choice should factor in regional variations, patient-specific characteristics, cost, accessibility, and potential drug interactions. (Source: High Blood Pressure and Cardiovascular Prevention)
Source: High Blood Pressure and Cardiovascular Prevention - April 1, 2024 Category: Cardiology Source Type: research
Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome
This study included ACS patients who underwent percutaneous coronary intervention and, at discharge between January 1, 2018 and December 31, 2020, were prescribed with low-dose prasugrel plus aspirin or standard-dose ticagrelor plus aspirin. Stabilized inve rse probability of treatment weighting was used to balance the covariates across these two groups. The primary effectiveness outcome was a composite of acute myocardial infarction, ischemic stroke, and cardiovascular death; the secondary effectiveness outcome was each of the individual components of the primary outcome, transient ischemic attack, and repeat revasculariz...
Source: Journal of Thrombosis and Thrombolysis - March 31, 2024 Category: Hematology Source Type: research
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
ConclusionAmong adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 29, 2024 Category: Endocrinology Source Type: research
A woman with eptifibatide (integrilin) ‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review
AbstractEptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition. However, this medication use is accompanied by complications in some cases. Thrombocytopenia which is a relatively common condition in patients admitted to the hospital, especially in the acute setting, can be caused by medications. This condition can occur as an antibody or non-antibody-mediated process, caused by medications, such as heparin, clopidogrel, and eptifibatide. In this case, we present a woman with acute coronar...
Source: Clinical Case Reports - March 28, 2024 Category: General Medicine Authors: Morteza Safi,
Roozbeh Nazari,
Nahid Senobari,
Homa Taheri,
Pouya Ebrahimi Tags: CASE REPORT Source Type: research
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
ConclusionAmong adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 27, 2024 Category: Endocrinology Source Type: research
It's time to overcome the "One-Size-Fits-All" approach in chronic coronary syndrome?
Chronic coronary syndrome (CCS) refers to a wide spectrum of clinical conditions characterized by clinically stable progression of coronary artery disease (CAD) [1]. Current guidelines recommend the administration of dual antiplatelet therapy (DAPT) with cardioaspirin and clopidogrel for 6 months for patients undergoing elective percutaneous coronary intervention (PCI) [1]. However, patients with CCS represent a heterogeneous population and the type and duration of DAPT can be modulated weighting the individual ischemic and hemorrhagic risks [1]. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 27, 2024 Category: Cardiology Authors: Giampaolo Niccoli, Filippo Luca Gurgoglione Tags: Editorial Source Type: research
It Is Time to Overcome the “One-Size-Fits-All” Approach in Chronic Coronary Syndrome?
Chronic coronary syndrome (CCS) refers to a wide spectrum of clinical conditions characterized by clinically stable progression of coronary artery disease (CAD).1 Current guidelines recommend the administration of dual antiplatelet therapy (DAPT) with cardioaspirin and clopidogrel for 6 months for patients who underwent elective percutaneous coronary intervention (PCI).1 However, patients with CCS represent a heterogeneous population, and the type and duration of DAPT can be modulated weighting the individual ischemic and hemorrhagic risks. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 27, 2024 Category: Cardiology Authors: Giampaolo Niccoli, Filippo Luca Gurgoglione Tags: Editorial Source Type: research
Factors Associated with Clopidogrel Resistance and Clinical Outcomes in Ischemic Cerebrovascular Disease: A Retrospective Study
Clopidogrel resistance may lead to the recurrence of cerebrovascular diseases. We aimed to identify potential factors associated with clopidogrel resistance and evaluate the clinical outcomes of the patients. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - March 19, 2024 Category: Neurology Authors: Yanzi Wu, Huachao Shen, Biyang Cai, Chen Chen, Qiong Yin, Yulei Zhao, Guohua Zhou Source Type: research
Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance study
CONCLUSION: We found that the risk of bleeding in patients taking Crude low molecular weight heparins was significantly higher compared to other antithrombotic agents, but with a small magnificence, which may be attributed to the severely irrational use of this medication under improper management. Statistics in days, results showed that the risk of bleeding decreased over time for warfarin and clopidogrel and increased for alteplase, nadroparin, and dipyridamole.PMID:38497691 | DOI:10.1080/14740338.2024.2327502 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 18, 2024 Category: Drugs & Pharmacology Authors: Kangyuan Guo Ganyi Wang Li Zhang Zhanchun Feng Xudong Xia Xiaobo Sun Ziqi Yan Zhiming Jiao Da Feng Source Type: research
Contribution of platelets to disruption of the blood-brain barrier during arterial baroreflex dysfunction
CONCLUSION: During ABR dysfunction, platelets may disrupt the blood-brain barrier when CD40L on their surface activates NF-kB signaling within cerebral microvascular endothelial cells, leading to upregulation of matrix metalloprotease-9. Our findings imply that targeting CD40L may be effective against cerebral diseases involving ABR dysfunction.PMID:38493885 | DOI:10.1016/j.mvr.2024.104681 (Source: Cell Research)
Source: Cell Research - March 17, 2024 Category: Cytology Authors: Bowen Shen Lili Yang Xiaoli Jia Deping Kong Yongfeng Gao Shan Gao Ruimin Chen Fengbao Chen Chunyu Zhao Yue Li Rui Tan Xiaomin Zhao Source Type: research
Antithrombotic strategies for preventing graft failure in coronary artery bypass graft
This article aims to inform clinical decision-making and guide the selection of antithrombotic strategies after CABG. (Source: Journal of Thrombosis and Thrombolysis)
Source: Journal of Thrombosis and Thrombolysis - March 16, 2024 Category: Hematology Source Type: research
